nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2020-24-6-65-70nefr-1902Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯORIGINAL ARTICLES. CLINICAL INVESTIGATIONSЭффективность и безопасность применения метоксиполиэтиленгликоль-эпоэтина бета у больных на диализе при конверсии с эпоэтинов короткого действияThe efficiency and safety of methoxy polyethylene glycol-epoetin beta usage in patients with dialysis, who are transitioning from short-acting epoethinshttps://orcid.org/0000-0002-2062-0421ШормановИ. С.ShormanovI. S.

Проф. Шорманов Игорь Сергеевич, д-р мед. наук, кафедра урологии с нефрологией

150000, Ярославль, ул. Революционная, д. 5Тел.: +7(4852)30-56-41 

Prof. Igor S. Shormanov, MD, PhD, DMedSci, Department of Urology and Nephrology

150000, Yaroslavl, Revolutsionnaya st., 5Phone: +7(4852)30-56-41 

i-s-shormanov@yandex.ruhttps://orcid.org/0000-0002-0102-1204ДубровА. И.DubrovA. I.

Дубров Александр Игоревич, канд. мед. наук, заместитель директора по медицинской части

150000, Ярославль, Тутаевское шоссе, д. 29Тел.: +7(960)537-89-02 

Alexander I. Dubrov, MD, PhD, Deputy Director of the medical Department

150000, Yaroslavl, Tutaevskoe shosse, 29Phone: +7(960)537-89-02 

aidubrov@mail.ruhttps://orcid.org/0000-0003-2464-572XЖигаловС. А.ZhigalovS. A.

Асс. Жигалов Сергей Алексеевич, канд. мед. наук, кафедра урологии с нефрологией

Assistant prof. Sergei A. Zhigalov, MD, PhD, Department of Urology and Nephrology

150000, Yaroslavl, Revolutsionnaya st., 5Phone: +7(915)970-92-51 

sergey.zhigalow@gmail.comЯрославский государственный медицинский университетРоссияYaroslavl State Medical UniversityRussian FederationЯрославский диализный центрРоссияYaroslavl dialysis centerRussian Federation2020251120202466570Copyright © Шорманов И.С., Дубров А.И., Жигалов С.А., 20202020Шорманов И.С., Дубров А.И., Жигалов С.А.Shormanov I.S., Dubrov A.I., Zhigalov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/1902гемодиализанемияактиватор рецепторов эритропоэтина длительного действияhemodialysisanemiacontinuous erythropoietin receptor activatorReferencesMacdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006;368:947-953. doi: 10.1016/s0140-6736(06)69120-4Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006;368:947-953. doi: 10.1016/s0140-6736(06)69120-4Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesisstimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-440Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesisstimulating agent for the treatment of anemia. Curr Hematol Rep 2005;4:436-440Jarsch M, Brandt M, Lanzendörfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63-69. doi: 10.1159/000109166Jarsch M, Brandt M, Lanzendörfer M et al. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008;81:63-69. doi: 10.1159/000109166Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-1215. doi: 10.2215/cjn.00730306Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-1215. doi: 10.2215/cjn.00730306Locatelli F, Mann J, Aldigier J et al. C.E.R.A. safety profile a pooled analysis in patients with chronic kidney disease. Clin Nephrol 2010;73:94-103. doi: 10.5414/cnp73094Locatelli F, Mann J, Aldigier J et al. C.E.R.A. safety profile a pooled analysis in patients with chronic kidney disease. Clin Nephrol 2010;73:94-103. doi: 10.5414/cnp73094Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4(5):1205-1213Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4(5):1205-1213Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210. doi: 10.2215/cjn.01110306Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-1210. doi: 10.2215/cjn.01110306Pisoni RL, Bragg-Gresham JL, Fuller DS et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 2011;57(2):266-275. doi: 10.1053/j.ajkd.2010.11.003Pisoni RL, Bragg-Gresham JL, Fuller DS et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 2011;57(2):266-275. doi: 10.1053/j.ajkd.2010.11.003Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-3170. doi: 10.1681/asn.2007010058Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007;18:3164-3170. doi: 10.1681/asn.2007010058Manley H, Debra R, Drayer R et al. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol 2003;4:4-10. doi: 10.1186/1471-2369-4-10Manley H, Debra R, Drayer R et al. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol 2003;4:4-10. doi: 10.1186/1471-2369-4-10Tabata H, Kanno H, Murayama A et al. Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study. Ren Replace Ther 2019;25(5). doi: 10.1186/s41100-019-0221-zTabata H, Kanno H, Murayama A et al. Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study. Ren Replace Ther 2019;25(5). doi: 10.1186/s41100-019-0221-zDuman N, Uyanik A, Unsal A et al. Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia. Clin Kidney J 2014;7(5):464-469. doi: 10.1093/ckj/sfu079Duman N, Uyanik A, Unsal A et al. Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia. Clin Kidney J 2014;7(5):464-469. doi: 10.1093/ckj/sfu079Barhoumi T, Briet M, Kasal DA et al. Erythropoietin-induced hypertension and vascular injury in mice overexpressing human endothelin-1: exercise attenuated hypertension, oxidative stress, inflammation and immune response. J Hypertens 2014;32:784-794. doi: 10.1097/HJH.0000000000000101Barhoumi T, Briet M, Kasal DA et al. Erythropoietin-induced hypertension and vascular injury in mice overexpressing human endothelin-1: exercise attenuated hypertension, oxidative stress, inflammation and immune response. J Hypertens 2014;32:784-794. doi: 10.1097/HJH.0000000000000101Briet M, Barhoumi T, Mian MO et al. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc 2013;2:e000128. doi: 10.1161/jaha.113.000128Briet M, Barhoumi T, Mian MO et al. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc 2013;2:e000128. doi: 10.1161/jaha.113.000128Agarwal R. Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. Nephrology Dialysis Transplantation 2018;33(10):1690-1698. doi: 10.1093/ndt/gfx324Agarwal R. Mechanisms and mediators of hypertension induced by erythropoietin and related molecules. Nephrology Dialysis Transplantation 2018;33(10):1690-1698. doi: 10.1093/ndt/gfx324

The authors declare that there are no conflicts of interest present.